RxDoctor Payments Data

Margaret Wagner, PA

Physician Assistant · Indianapolis, INNPI 1437878055

Payments from drug & device makers

$3,771in general payments, 2019–2025

Across 231 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$658
  • AstraZeneca$544
  • Novo Nordisk$492
  • Lilly USA, LLC$348
  • Corcept Therapeutics$306
  • Amgen$151
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$3,74299%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,771 in reported general payments places this provider in the 90th percentile of 1,955 physician assistant providers in Indiana.

See all physician assistant providers in Indiana

Medicare billing

Part B allowed, 2024
$64,490
Medicare patients
178
Services billed
1,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$61,284
MounjaroTirzepatide50$48,736
JardianceEmpagliflozin19$28,620
EliquisApixaban15$24,821
TrulicityDulaglutide12$15,851
Tresiba Flextouch U-200Insulin Degludec12$7,037
Memantine Hcl ErMemantine Hcl13$3,962
Losartan Potassium156$1,594
Levothyroxine Sodium173$1,579
Omeprazole97$1,418
Metoprolol Succinate122$1,360
Rosuvastatin Calcium107$1,296
Atorvastatin Calcium224$1,264
Amlodipine Besylate152$959
Gabapentin61$850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$348$64,58762 claims
Novo NordiskOzempic$492$61,28444 claims
Boehringer IngelheimJardiance$31$28,62019 claims
PfizerEliquis$126$24,82115 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,579173 claims
AbbVieSynthroid$658$75116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,955 physician assistant providers in Indiana.

Other physician assistant in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →